No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Wednesday, October 1, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Medicare

As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off

by TheAdviserMagazine
4 weeks ago
in Medicare
Reading Time: 5 mins read
A A
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Share on FacebookShare on TwitterShare on LInkedIn


After losing 50 pounds on the injectable weight loss medication Zepbound, Kyra Wensley received a surprising letter from her pharmacy benefit manager in April.

Her request for coverage had been denied, the letter said, because she’d had a body mass index of less than 35 when she started Zepbound. The 25-year-old who lives in New York had been taking Zepbound without incident for months, so she was confused: Why was her BMI, which had been around 32 when she started, becoming an issue only now?

Wensley had no interest in quitting an effective drug. “Going right off like that, it’s easier said than done,” she said.

Kyra Wensley’s doctor fought to keep her on the injectable weight loss medication Zepbound, but Wensley ultimately had to switch to Wegovy, a different GLP-1 agonist, to meet her health plan’s requirements.(Lori Wensley)

Her doctor fought to keep her on the GLP-1 agonist, the category that includes weight loss and Type 2 diabetes drugs Ozempic, Wegovy, Mounjaro, and Zepbound. But Wensley ultimately had to switch from Zepbound to Wegovy to meet her plan’s requirements. She said she doesn’t like Wegovy as much as her old medication, but she now feels lucky to be on any GLP-1.

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But with list prices of roughly $1,000 a month, public and private payers are struggling to keep up with ballooning demand for GLP-1 weight loss drugs and in some cases are eliminating or restricting their coverage as a result.

North Carolina Medicaid plans to end GLP-1 coverage for weight loss on Oct. 1, just over a year after starting the coverage. Pennsylvania is planning to limit Medicaid coverage to beneficiaries at the highest risk of complications from obesity. And despite recent reports of a potential federal pilot program to extend coverage of GLP-1 obesity drugs under Medicaid and Medicare, all state Medicaid programs are likely to be under pressure due to steep spending cuts in the budget reconciliation package recently signed into law by President Donald Trump.

Already, many GLP-1 users quit within a year, studies suggest — often due to side effects, high costs, or insurance issues. Now a growing number of researchers, payers, and providers are exploring deliberate “deprescription,” which aims to taper some patients off their medication after they have taken it for a certain amount of time or lost a certain amount of weight.

The U.K.’s National Institute for Health and Care Excellence, which creates guidance for the National Health Service, recommends two-year limits on the use of some weight loss medications, such as Wegovy. And the concept was raised in a recent Institute for Clinical and Economic Review report on affordable access to obesity drugs.

A. Mark Fendrick, who directs the Center for Value-Based Insurance Design at the University of Michigan, has argued that if some people using GLP-1s to lose weight were eventually transitioned off, more people could take advantage of them.

“If you’re going to spend $1 billion or $100 billion, you could either spend it on fewer people for a long period of time, or you can spend it on a lot more people for a shorter period of time,” he said.

Email Sign-Up

Subscribe to KFF Health News’ free Morning Briefing.

Fendrick’s employer, the University of Michigan, indeed does that. Its prescription drug plan caps coverage of GLP-1 drugs at two years if they’re used solely for weight loss.

Jamie Bennett, a spokesperson for Wegovy and Ozempic maker Novo Nordisk, declined to comment on the concept of deprescription, noting that its drugs are intended for chronic conditions. Rachel Sorvig, a spokesperson for Zepbound and Mounjaro manufacturer Eli Lilly, said in a statement that users should “talk to their health care provider about dosage and duration needs.”

Studies have shown that people typically regain a substantial amount of weight within a year of stopping GLP-1 medications, and that many people who quit ultimately go back on the drugs.

“There’s no standard of care or gold standard on how to wean right now,” said Allison Adams, an obesity and internal medicine doctor with UK HealthCare in Kentucky.

But the math shows why time-limited coverage is appealing to payers that struggle to pay for beneficiaries’ GLP-1 prescriptions, said Michelle Gourdine, chief medical officer for the pharmacy benefit manager CVS Caremark.

And states are “between a rock and a hard place,” said Kody Kinsley, who until January led North Carolina’s Health and Human Services Department. “They’re going to have to look at every single thing and trim dollars everywhere they can.”

Pennsylvania was looking for cost-saving strategies even before the new federal tax-and-spending law, according to Brandon Cwalina, press secretary for the state’s Department of Human Services. Pennsylvania projects it will spend $1.3 billion on GLP-1 drugs this year.

Plans could see real savings, Fendrick said, if they covered GLP-1s for initial weight loss then moved people to cheaper options — such as more affordable drugs or behavioral health programs — to maintain it.

Plenty of companies are eager to sell insurers, employers, and individuals on behavioral alternatives. One is Virta Health, which advertises its nutrition-focused weight management program as “a proven approach for deprescribing GLP-1s when clinically appropriate.” A Virta-funded study assessed 154 people with Type 2 diabetes who stopped using GLP-1 medications but continued following Virta’s program, concluding that their weight did not significantly increase after a year.

Researchers affiliated with a European weight management company also recently reported that slowly tapering off the medications may help maintain weight loss.

For employers and insurers, the “initial question” was whether to cover GLP-1s for obesity, said Virta CEO Sami Inkinen. “Now, basically, everyone’s coming to the middle and asking, ‘How do we responsibly cover these drugs?’”

Part of responsible coverage, Inkinen said, is providing other forms of support to patients who stop using GLP-1 medications, by choice or otherwise.

For some people, however, maintaining weight loss without a GLP-1 remains a challenge, even with other options available.

Lily, who lives in Michigan, lost almost 80 pounds in roughly 18 months on Wegovy. But she had to quit the drug when she turned 26 and left her parents’ insurance plan this year. The plan her employer offers stopped covering GLP-1s for weight loss right around the time she joined.

Lily, who asked to be identified by only her first name because she is not out to her family as transgender, has tried other medications since then, and previously tried lifestyle programs to control her weight. But she said nothing works as well for her as Wegovy.

She has regained 20 pounds since going off the drug at the beginning of the year and worries that number will continue to rise, potentially contributing to future health problems.

“Just give people the drugs,” she said. “It seems cheaper and safer in the long run.”

Related Topics

Contact Us

Submit a Story Tip



Source link

Tags: CostsdrugGLP1InsurerspatientsseekStruggleWean
ShareTweetShare
Previous Post

Football Players | Nonresident Income Tax Filing

Next Post

What if artificial intelligence is just a “normal” technology?

Related Posts

edit post
Health insurance for the unemployed

Health insurance for the unemployed

by TheAdviserMagazine
September 28, 2025
0

In the United States, nearly half of the people under the age of 65 get their health insurance from an...

edit post
Journalists Recap Coverage on Organ Harvesting, Obamacare, and Medicaid Cuts

Journalists Recap Coverage on Organ Harvesting, Obamacare, and Medicaid Cuts

by TheAdviserMagazine
September 27, 2025
0

KFF Health News Midwest correspondent Cara Anthony discussed problems with the organ transplantation industry on Apple News’ “Apple News Today”...

edit post
Listen: Young Adults Turning 26 Face Health Insurance Cliff

Listen: Young Adults Turning 26 Face Health Insurance Cliff

by TheAdviserMagazine
September 26, 2025
0

Thank you for your interest in supporting KFF Health News, the nation’s leading nonprofit newsroom focused on health and health...

edit post
Federal Funding Deadline Looms – Medicare Rights Center

Federal Funding Deadline Looms – Medicare Rights Center

by TheAdviserMagazine
September 25, 2025
0

Legislation funding the federal government expires September 30. Congress must pass another spending bill by then to avoid a shutdown,...

edit post
Final Rule and New Special Enrollment Period Will Aid Those Misled by Provider Directories

Final Rule and New Special Enrollment Period Will Aid Those Misled by Provider Directories

by TheAdviserMagazine
September 25, 2025
0

Earlier this month, we flagged important changes coming to Medicare Plan Finder (MPF) for the upcoming Fall Open Enrollment period,...

edit post
Amid Confusion Over US Vaccine Recommendations, States Try To ‘Restore Trust’

Amid Confusion Over US Vaccine Recommendations, States Try To ‘Restore Trust’

by TheAdviserMagazine
September 24, 2025
0

When the CDC’s Advisory Committee on Immunization Practices met last week, confusion filled the room. Members admitted they didn’t know...

Next Post
edit post
What if artificial intelligence is just a “normal” technology?

What if artificial intelligence is just a “normal” technology?

edit post
Sam Altman Says Rise in Twitter Bots Lends Credence to Dead Internet Theory

Sam Altman Says Rise in Twitter Bots Lends Credence to Dead Internet Theory

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Who Needs a Trust Instead of a Will in North Carolina?

Who Needs a Trust Instead of a Will in North Carolina?

September 1, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
US markets regulators start shuttering as government shutdown cuts federal funding

US markets regulators start shuttering as government shutdown cuts federal funding

0
edit post
Shutdown, Clampdown, Clownshow or Horror Movie?

Shutdown, Clampdown, Clownshow or Horror Movie?

0
edit post
XRP Flips Green For First Time Since 2017, Pundit Predicts 500% Rally

XRP Flips Green For First Time Since 2017, Pundit Predicts 500% Rally

0
edit post
How to build confidence in your financial life

How to build confidence in your financial life

0
edit post
LVMH: Top-Analystenhäuser heben die Daumen!

LVMH: Top-Analystenhäuser heben die Daumen!

0
edit post
AI godfather warns humanity risks extinction by hyperintelligent machines with their own ‘preservation goals’ within 10 years

AI godfather warns humanity risks extinction by hyperintelligent machines with their own ‘preservation goals’ within 10 years

0
edit post
Shutdown, Clampdown, Clownshow or Horror Movie?

Shutdown, Clampdown, Clownshow or Horror Movie?

October 1, 2025
edit post
XRP Flips Green For First Time Since 2017, Pundit Predicts 500% Rally

XRP Flips Green For First Time Since 2017, Pundit Predicts 500% Rally

October 1, 2025
edit post
AI godfather warns humanity risks extinction by hyperintelligent machines with their own ‘preservation goals’ within 10 years

AI godfather warns humanity risks extinction by hyperintelligent machines with their own ‘preservation goals’ within 10 years

October 1, 2025
edit post
AI Agents Have Entered the Real World

AI Agents Have Entered the Real World

October 1, 2025
edit post
LVMH: Top-Analystenhäuser heben die Daumen!

LVMH: Top-Analystenhäuser heben die Daumen!

October 1, 2025
edit post
Meet the end-of-life planning startup co-founded by NBA All Star Russell Westbrook

Meet the end-of-life planning startup co-founded by NBA All Star Russell Westbrook

October 1, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Shutdown, Clampdown, Clownshow or Horror Movie?
  • XRP Flips Green For First Time Since 2017, Pundit Predicts 500% Rally
  • AI godfather warns humanity risks extinction by hyperintelligent machines with their own ‘preservation goals’ within 10 years
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.